About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 136 record(s)
Req # A-2020-00813
Copies of documents related to the use of the excessive price penalty against Alexion Pharmaceuticals.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2021-00815
Copies of all emails to/from cc'ing Guillaume Coullaird regarding the use of the excessive prices penalty and future use against pharmaceutical companies from January 1, 2019 to January 18, 2021.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2021-01073
Copies of all emails to/from and cc'ing Douglas Clark, Mitchell Levine and Melanie Bourassa-Forcier regarding the decision to delay the implementation of the PMPRB guidelines to Summer 2021 from November 1, 2020 to January 20, 2021.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2021-01083
Copies of all emails to/from and cc'ing Douglas Clark, Mitchell Levine and Melanie Bourassa-Forcier regarding any directives from the Health minister's office regarding the implementation of the new PMPRB guidelines from January 1, 2020 to January 20, 2021.Organization: Patented Medicine Prices Review Board Canada
February 2021
Req # A-2020-00035
All Temporary Help Services (THS) Supply Arrangement (SA) and Standing Offer (SO) callups issued in the National Capital Region for the months of July 2020, August 2020, & September 2020.Organization: Canadian Transportation Agency
December 2020
Req # A-2020-18435
All briefing notes, memos, PowerPoints, policy briefs and reports submitted to the ISED Minister from June 1, 2019 to November 19, 2020.Organization: Patented Medicine Prices Review Board Canada
December 2020
Req # A-2020-18732
A detailed summary of the PMPRB's use of the excessive price penalty on pharmaceutical companies from June 1, 2019 to November 26, 2020. For each penalty, break it down by date, company charged, drug in question, and fine levied.Organization: Patented Medicine Prices Review Board Canada
December 2020
Req # A-2020-00017
Documents related to Air Canada held by the Canadian Transportation Agency. Please also provide me with copies of all documents, including e-mail messages and letters, that the CTA holds that contain "National Airlines Council of Canada" and/or "NACC" in their content or metadata and which were created or last modified since 2020-03-15.Organization: Canadian Transportation Agency
November 2020
Req # A-2020-00027
All documents or submissions filed in support of Consumer's Gas's application to relocate its 20 inch natural gas pipeline along the bridge of the Toronto Harbour Commissioner's in the vincity of Lake Share Boulevard (formerly Keating Street), and any communications or documents prepared by the Board of Transport in respect of this application. A copy of the Order of the Board of Transport Commissioners for Canada dated June 26, 1962 is attached for reference. The Order No. is 108226. The Board's file number is 45562.1.Organization: Canadian Transportation Agency
September 2020
Req # A-2020-09098
Copies of all records discussing the impacts of the regulatory changes to the PMPRB from August 2019 until August 2020. Copies of all correspondence from all pharmaceutical companies expressing their concerns with the changes and any responses back to these companies. Copies of all correspondence from all advocating groups expressing concerns with the changes and any responses back to these groups. Copies of all correspondence between departmental staff discussing the impacts of the regulatory changes to the PMPRB. Copies of all records discussing the impacts of the PMPRB changes on individuals living with rare diseases. Copies of all correspondence from Vertex Pharmaceuticals relating to Kalydeco, Orkambi, Symdeko, and Trikafta. Copies of all correspondence between government officials (Prime Minister, Ministers, all members of parliament, constituency staff, deputies, assistant deputies, directors, managers, supervisors, staff, and any other employee of the Government of Canada relating to the PMPRB regulatory changes. Copies of all presentations relating to the PMPRB regulatory changes.Organization: Patented Medicine Prices Review Board Canada
September 2020